Stanislas Veillet, CEO of Biophytis, analyses on BOURSIER.COM the new development cycle of Biophytis and reviews the clinical successes of the COVA, SARA, MYOCA and MACA studies which are in the Biophytis pipeline.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok